Is ketamine an effective treatment for depression?

Yes — for a defined subset of patients. Randomized trials show that sub-anesthetic ketamine and intranasal esketamine (Spravato, FDA-approved 2019) can produce rapid reductions in symptoms of treatment-resistant depression, with effects typically emerging within hours and lasting days to weeks. Ketamine is a legitimate, evidence-based tool in psychiatric care.

What are the known risks of ketamine therapy?

Documented risks include dissociation during infusion, transient blood-pressure elevation, and — with frequent recreational use or unmonitored repeat infusions — bladder toxicity (ketamine cystitis) and cognitive effects. Risk profiles differ sharply between medically supervised protocols and high-frequency off-label use.

How is Sanctuary Tulum's Brain Repair IV different from ketamine?

It is a different intervention with different mechanisms and goals. The Brain Repair IV delivers amino acids and cofactors intended to support neurotransmitter synthesis and recovery from prolonged medication or substance exposure. It is not a psychiatric medication and is not a substitute for evidence-based depression treatment when that is clinically indicated.

Can I use both approaches?

Some guests arrive already on a psychiatric medication regimen that includes ketamine or other agents. All medications are reviewed by our medical team on intake, and any changes are coordinated with the guest's prescribing physician — never made unilaterally.

Synthetic Ketamine vs Natural Brain Repair IVs

Ketamine has moved rapidly from anesthesia into mainstream psychiatric care over the last decade. It is a legitimate, evidence-based tool for a defined subset of patients — and it is also frequently marketed in ways that overstate its role. This article compares ketamine-assisted therapy honestly to Sanctuary Tulum's amino acid-based Brain Repair IV protocol, so guests can understand what each is, what each isn't, and how the two fit into a broader recovery plan.

How Ketamine Works

Ketamine is a dissociative anesthetic that acts primarily as an NMDA glutamate receptor antagonist. At sub-anesthetic doses it produces rapid reductions in depressive symptoms — often within hours — that can last days to several weeks. A widely cited review in Neuron summarized the shift ketamine represented in depression research and treatment¹. In 2019 the FDA approved intranasal esketamine (Spravato) for treatment-resistant depression, and a 2023 meta-analysis in The BMJ examined the efficacy of racemic ketamine and esketamine across the published trial base².

The effect is real and, for patients who have not responded to first-line treatments, often meaningful. It is also not curative on its own: symptom reduction typically wanes over days to weeks, which is why clinical protocols involve a series of infusions and ongoing maintenance. Documented risks include acute dissociation, transient blood pressure elevation, and — with frequent, unmonitored use — urinary tract toxicity and cognitive effects. A safety review in Journal of Clinical Psychiatry catalogued these considerations in the psychiatric-use context³.

What the Brain Repair IV Is (and Isn't)

Sanctuary Tulum's Brain Repair IV is a different intervention with different goals. It delivers a concentrated blend of amino acids and cofactors intended to support neurotransmitter synthesis and cellular energy during and after a period of prolonged medication, substance, or stress exposure. It is used most often for guests tapering from long-term benzodiazepine, opioid, or stimulant exposure, and in the days surrounding ayahuasca ceremonies or ibogaine treatment. It is not a psychiatric medication, is not FDA-approved for the treatment of depression, and is not presented as an equivalent or a replacement for ketamine when ketamine is clinically indicated.

Used together with NAD+ IV therapy, which supports mitochondrial function and cellular repair, the intent of the Brain Repair IV protocol is to stabilize neurochemistry during a period of significant biological change — not to treat major depressive disorder as a standalone intervention.

Side-by-Side Comparison

Factor	Ketamine / Esketamine	Brain Repair IV
Regulatory status	FDA-approved (esketamine) for TRD; racemic ketamine used off-label	Nutritional infusion; not a psychiatric drug
Primary mechanism	NMDA receptor antagonism	Amino acid / cofactor delivery for neurotransmitter synthesis
Onset of effect	Hours	Days, as part of a broader recovery protocol
Duration of a single dose	Days to weeks	Cumulative support across the stay
Known risks	Dissociation, BP changes, bladder toxicity with frequent use	Generally well tolerated; screened for allergies and interactions

How to Think About the Two

Ketamine and the Brain Repair IV answer different clinical questions. Ketamine can produce rapid symptom reduction in treatment-resistant depression when delivered in a properly supervised setting. The Brain Repair IV is a supportive infusion intended to stabilize neurochemistry during a broader recovery process. Neither is a substitute for the other; both are tools with defined indications and defined limits.

Guests considering Sanctuary Tulum are screened by our medical team, and every current medication — including ketamine, SSRIs, MAOIs, and benzodiazepines — is reviewed before any protocol is scheduled. Changes to psychiatric medications are coordinated with the guest's prescribing physician, not made unilaterally. Learn more about our approach to integrative biohacking and the Pouyan Method™.